Tradestie Institutional Equity Comparison Engine

MTNB vs ANRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANRO Overall Edge

ANRO Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical while MTNB counters with relative strength in Options & Structure. Fundamentally, MTNB trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MTNB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
MTNB N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner ANRO
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner ANRO
1Y -1.0% vs +63.3% ยท 52W Pos 22% vs 52%
Options & Structure Winner MTNB
UNCLASSIFIED (N/A IV) vs BREAKDOWN (8th %ile IV)
MTNB NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.80
-1.26% 1D
Market Cap $902,069
1M Return -53.22%
1Y Return -1.01%
Forward P/E N/M
Unified AI Score
52.8 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 50.0 Mom 60.0
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.37
-4.3% 1D
Market Cap $1.1B
1M Return +14.28%
1Y Return +63.26%
Forward P/E N/M
Unified AI Score
45.8 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MTNB -1.01% ANRO +63.26% Spread: +64.27 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MTNB TTM Op. Margin: 0.0% ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MTNB vs ANRO. Trailing 12-month operating profitability (MTNB 0.0% vs ANRO 0.0%) and valuation multiples (MTNB N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MTNB (1) vs ANRO (5)
Institutional Metric MTNB ANRO Criterion Row Winner
Market Capitalization Scale $902,069 $1.1B Larger Scale ANRO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% +0.0% Higher Growth ANRO
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -147.5% -46.7% Higher ROE ANRO
52-Week Range Position Momentum 22% ($0โ€“$3) 52% ($13โ€“$37) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime -6.35ฮฒ ยท 138% Vol 1.86ฮฒ ยท 91% Vol Lower Realized Risk ANRO
Unified Institutional Score Composite Signal 52.8 / 100 (HOLD) 45.8 / 100 (HOLD) Higher Composite MTNB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MTNB vs ANRO Buy Guide
MTNB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MTNB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
61d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MTNB nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.